{"id":886300,"date":"2025-09-15T11:39:41","date_gmt":"2025-09-15T15:39:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\/"},"modified":"2025-09-15T11:39:41","modified_gmt":"2025-09-15T15:39:41","slug":"forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\/","title":{"rendered":"Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistcircle { list-style-type: circle }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium<\/b><\/p>\n<p class=\"bwalignc\"><i>Additional data continues to support highly differentiated profile for FB102 in celiac disease<\/i><\/p>\n<p>DALLAS&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nForte Biosciences, Inc. (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54323242&amp;newsitemid=20250915660032&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=b22edb7a65bf066e780d8b45a2a9c011\">www.fortebiorx.com<\/a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced additional details from the oral presentation \u201cFB102 prevents histological damage and mitigates gluten challenge-induced symptoms in a celiac disease phase 1b study<i> &#8211; Jason Tye-Din, Walter and Eliza Hall Institute; Royal Melbourne Hospital<\/i>\u201d at the Tampere Celiac Disease Symposium 2025 (Tampere, Finland) on Friday September 12, 2025, further supporting the significant differentiation of FB102 in celiac disease.<\/p>\n<p>\nHighlights of the oral presentation include:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nFB102 demonstrated a decline in the TCR \u03b3\u03b4 density from baseline of 1.5 compared to an increase of 3.9 for placebo (p=0.0007)<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nTCR \u03b3\u03b4 cells produce pro-inflammatory cytokines including IFN-\u03b3 and TNF-\u03b1 and upregulate activating receptors on epithelial cells triggering cytotoxic responses that directly kill the epithelial cells.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\nKi67-positive intraepithelial cell density increased from baseline by 8.6 on placebo compared to 2.5 on FB102 (p=0.0006)<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nKi67 is a marker of T cell proliferation (inflammation) on gluten exposure in celiac disease<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\nNK cells declined by 95% following FB102 dosing<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nIL-15 upregulates activating receptors and confers resistance to activation-induced cell death and enhances T cell epithelial cytotoxicity in celiac disease. NK cell reduction is a marker of IL-15 pathway inhibition.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\nNo statistically significant difference in Tregs between FB102 and placebo at any timepoint.<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nRegulatory T cells (Tregs) help to modulate the immune response in autoimmune diseases like celiac disease.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n\u201cWe want to thank all of the clinical trial sites for participating in the FB102-101C study,\u201d said Forte Biosciences CEO Paul Wagner, PhD. \u201cThe results presented by Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute at the Royal Melbourne Hospital and principal investigator in the FB102 phase 1b trial, at the Tampere Celiac Disease Symposium further reinforce the differentiation of FB102 in celiac disease. The phase 2 FB102 celiac disease trial is underway with topline data coming in 2026. The FB102 impact on the additional IEL subtypes in the phase 1b trial is extremely encouraging with respect to the additional therapeutic indications Forte is pursuing, including vitiligo and alopecia areata with data from both of these trials expected next year.<\/p>\n<p>\nAdditional details can be found in the presentations posted to the investor relations section of Forte\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com&amp;esheet=54323242&amp;newsitemid=20250915660032&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=2&amp;md5=254d5695fb9fdf1a183a16fba71a99c6\">www.fortebiorx.com<\/a>.<\/p>\n<p><b>About Forte<\/b><\/p>\n<p>\nForte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nForte cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential\u201d or \u201ccontinue\u201d or the negatives of these terms or other similar expressions. These statements are based on the Company\u2019s current beliefs and expectations. Forward-looking statements include statements regarding the Company\u2019s beliefs, goals, intentions and expectations regarding its product candidate, FB102 and the therapeutic and commercial market potential of FB102, expectations for patient enrollment and timing of clinical data readouts. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: risks related to Forte\u2019s ability to obtain sufficient additional capital to continue to advance Forte\u2019s product candidate, FB102; uncertainties associated with the clinical development and regulatory approval of Forte\u2019s product candidate, FB102, including potential delays in the commencement, enrollment and completion of clinical trials, including the timing of the completion of the Company\u2019s patient-based trials; the risk that results from preclinical and any interim result of our ongoing clinical trials may not be predictive of future results from clinical trials; risks associated with the failure to realize any value from FB102 in light of inherent risks, expense and difficulties involved in successfully bringing product candidates to market; and additional risks, uncertainties, and other information affecting Forte\u2019s business and operating results is contained in Forte\u2019s Quarterly Report on Forms 10-Q filed on August 14, 2025, and in its other filings with the Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Forte undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.<\/p>\n<p>\nSource: Forte Biosciences, Inc.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250915660032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250915660032\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250915660032\/en\/<\/a><\/span><\/p>\n<p>\nLifeSci Advisors<br \/>\n<br \/>Mike Moyer, Managing Director<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:mmoyer@lifesciadvisors.com\">mmoyer@lifesciadvisors.com<\/a><\/p>\n<p>\nForte Biosciences, Inc.<br \/>\n<br \/>Paul Wagner, CEO<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@fortebiorx.com\">investors@fortebiorx.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Texas<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Infectious Diseases Health Pharmaceutical Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium Additional data continues to support highly differentiated profile for FB102 in celiac disease DALLAS&#8211;(BUSINESS WIRE)&#8211; Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced additional details from the oral presentation \u201cFB102 prevents histological damage and mitigates gluten challenge-induced symptoms in a celiac disease phase 1b study &#8211; Jason Tye-Din, Walter and Eliza Hall Institute; Royal Melbourne Hospital\u201d at the Tampere Celiac Disease Symposium 2025 (Tampere, Finland) on Friday September 12, 2025, further supporting the significant differentiation of FB102 in celiac disease. Highlights of the oral presentation include: FB102 demonstrated a decline in the TCR \u03b3\u03b4 density from &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-886300","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium Additional data continues to support highly differentiated profile for FB102 in celiac disease DALLAS&#8211;(BUSINESS WIRE)&#8211; Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced additional details from the oral presentation \u201cFB102 prevents histological damage and mitigates gluten challenge-induced symptoms in a celiac disease phase 1b study &#8211; Jason Tye-Din, Walter and Eliza Hall Institute; Royal Melbourne Hospital\u201d at the Tampere Celiac Disease Symposium 2025 (Tampere, Finland) on Friday September 12, 2025, further supporting the significant differentiation of FB102 in celiac disease. Highlights of the oral presentation include: FB102 demonstrated a decline in the TCR \u03b3\u03b4 density from &hellip; Continue reading &quot;Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-15T15:39:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250915660032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium\",\"datePublished\":\"2025-09-15T15:39:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\\\/\"},\"wordCount\":865,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250915660032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\\\/\",\"name\":\"Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250915660032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-09-15T15:39:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250915660032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250915660032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\/","og_locale":"en_US","og_type":"article","og_title":"Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium - Market Newsdesk","og_description":"Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium Additional data continues to support highly differentiated profile for FB102 in celiac disease DALLAS&#8211;(BUSINESS WIRE)&#8211; Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced additional details from the oral presentation \u201cFB102 prevents histological damage and mitigates gluten challenge-induced symptoms in a celiac disease phase 1b study &#8211; Jason Tye-Din, Walter and Eliza Hall Institute; Royal Melbourne Hospital\u201d at the Tampere Celiac Disease Symposium 2025 (Tampere, Finland) on Friday September 12, 2025, further supporting the significant differentiation of FB102 in celiac disease. Highlights of the oral presentation include: FB102 demonstrated a decline in the TCR \u03b3\u03b4 density from &hellip; Continue reading \"Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-15T15:39:41+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250915660032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium","datePublished":"2025-09-15T15:39:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\/"},"wordCount":865,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250915660032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\/","name":"Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250915660032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-09-15T15:39:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250915660032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250915660032r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-announces-presentation-of-fb102-celiac-disease-trial-at-tampere-celiac-disease-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/886300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=886300"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/886300\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=886300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=886300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=886300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}